MAP2K7 and neoplasm: Moreover, as the majority of patients with NF1 develop non-tumor-related comorbidities (e.g. cognitive deficits), a subset of which are not dependent on RAS-MEK activity, the identification of RAS-independent targetable proteins or pathways will be critical for their management.